Related content

Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma: A single institution's experience

By Tas Faruk   Kurul Sidika   Camlica Hakan   Topuz Erkan  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 471-477

Humana Press, Inc

Access to resources Recommend Favorite

Treatment for intermediate and high-risk prostate cancer: Controversial issues and the role of hyperthermia

By Maluta Sergio   Dall'oglio Stefano   Nadalini Luisa  

International Journal of Hyperthermia, Vol. 26, Iss. 8, 2010-12 ,pp. : 765-774

Informa Healthcare

Access to resources Recommend Favorite

Maintenance Therapy with Intravesical Bacillus Calmette-Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive Bladder Cancer

By Muto Satoru   Nakajima Akiko   Horiuchi Akira   Inoue Masayuki   China Toshiyuki   Saito Keisuke   Isotani Shuji   Hisasue Shin-ichi   Yamaguchi Raizo   Ide Hisamitsu   Horie Shigeo  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 3, 2013-03 ,pp. : 305-313

Oxford University Press

Access to resources Recommend Favorite

A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer

By Sousa Alejandro   Inman Brant A.   Piñeiro Idelfonso   Monserrat Victor   Pérez Alberto   Aparici Vincente   Gómez Isabel   Neira Pilar   Uribarri Carlos  

International Journal of Hyperthermia, Vol. 30, Iss. 3, 2014-05 ,pp. : 166-170

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain

By Gonzalez-Larriba J.L.   Serrano S.   Alvarez-Mon M.   Camacho F.   Casado M.A.   Daz-Perez J.L.   Daz-Rubio E.   Fosbrook L.   Guillem V.   Lopez-Lopez J.J.   Moreno-Nogueira J.A.   Toribio J.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2344-2352

Elsevier

Access to resources Recommend Favorite